EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fenofibrate Treatment Inhibits Very-Low-Density Lipoprotein Transport Vesicle Formation by Reducing Sar1b Protein Expression

Kayli Winterfeldt, Fahim Rejanur Tasin, Vandana Sekhar iD, Shadab A Siddiqi iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26104720 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kayli Winterfeldt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolic & Cardiovascular Sciences, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 6900 Lake…. Hauptthemen laut MEDLINE: Fenofibrate, Lipoproteins, VLDL, Monomeric GTP-Binding Proteins, Transport Vesicles. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dyslipidemia is a well-known risk factor in the development and progression of atherosclerosis. VLDL plays a crucial role in maintaining lipid homeostasis; however, even minor fluctuations in its production, intracellular trafficking, and secretion can contribute to the progression of atherosclerosis. Fenofibrate is an FDA-approved drug that effectively lowers plasma triglycerides and VLDL-associated cholesterol while simultaneously increasing HDL levels. Although fenofibrate is a known PPARα agonist with several proposed mechanisms for its lipid-altering effects, its impact on the intracellular trafficking of VLDL has not yet been investigated. We observed that treatment of HepG2 cells with 50 µM of fenofibrate resulted in a significant reduction in VLDL secretion, as evidenced by a significant decrease in the secretion of 3H-labeled TAG, fluorescent TAG, and ApoB100 protein into the media. Using confocal microscopy to monitor VLDL intracellular trafficking, we observed a distinct change in VLDL triglyceride localization, suggesting delayed transport through the endoplasmic reticulum and Golgi. An immunoblot analysis revealed a decrease in Sar1B protein expression, a key regulator of COPII protein recruitment, which is essential for VTV formation and intracellular VLDL trafficking, the rate-limiting step in VLDL secretion. Our data reveal a novel mechanism by which fenofibrate alters the lipid profile by interfering with intracellular VLDL trafficking in hepatocytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FenofibrateLipoproteins, VLDLMonomeric GTP-Binding ProteinsTransport VesiclesHypolipidemic AgentsHumansHep G2 CellsHepatocytesEndoplasmic ReticulumGolgi ApparatusProtein TransportTriglycerides

Stichwörter der Autor:innen

Golgiatherosclerosiscoat protein complex II (COPII)endoplasmic reticulum (ER)fenofibrateintracellular traffickingvery low-density lipoprotein (VLDL)

Substanzen

FenofibrateLipoproteins, VLDLMonomeric GTP-Binding ProteinsSAR1B protein, humanHypolipidemic AgentsTriglycerides

Autor:innen und Institutionen

  • Division of Metabolic & Cardiovascular Sciences, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 6900 Lake Nona Blvd., Room# 349, Orlando, FL 32827, USA.

ORCID-Profile: Vandana Sekhar, Shadab A Siddiqi

Förderung

  • NIDDK NIH HHS
  • National Institute of Health (NIH)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH)

Zitieren

APA

Winterfeldt, K., Tasin, F. R., Sekhar, V., & Siddiqi, S. A. (2025). Fenofibrate Treatment Inhibits Very-Low-Density Lipoprotein Transport Vesicle Formation by Reducing Sar1b Protein Expression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104720

Vancouver

Winterfeldt K, Tasin FR, Sekhar V, Siddiqi SA. Fenofibrate Treatment Inhibits Very-Low-Density Lipoprotein Transport Vesicle Formation by Reducing Sar1b Protein Expression. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104720

BibTeX
@article{Winterfeldt2025,
  author = {Winterfeldt, Kayli and Tasin, Fahim Rejanur and Sekhar, Vandana and Siddiqi, Shadab A},
  title = {Fenofibrate Treatment Inhibits Very-Low-Density Lipoprotein Transport Vesicle Formation by Reducing Sar1b Protein Expression},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26104720}
}
Kostenlos starten →